Durability of CRISPR-Cas9 Gene Editing Targeting ANGPTL3 with CTX310
New England Journal of Medicine · 01.10.2026 · 395 (13) · 1343-1345
DOI: 10.1056/nejmc2609825 ↗Kurz gefasst
Leserbrief in der Zeitschrift New England Journal of Medicine, erschienen am 01.10.2026. Verfasst von Luke J Laffin und 13 weiteren Autor:innen. Beteiligte Einrichtung: Cleveland Clinic Coordinating Center for Clinical Research, Cleveland. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 4 Literaturangaben. Gefördert von: CRISPR Therapeutics.
Abstract (Originalsprache)
In a phase 1a trial, one-time CRISPR-Cas9 gene editing with CTX310 was associated with no treatment-related dose-limiting toxic effects and with sustained reductions in ANGPTL3 and atherogenic lipids at 1 year.
Autor:innen und Institutionen
- Cleveland Clinic Coordinating Center for Clinical Research, Cleveland.
- Victorian Heart Institute, Melbourne, VIC, Australia.
- New Zealand Clinical Research, Christchurch, New Zealand.
- Royal Adelaide Hospital, Adelaide, SA, Australia.
- Aotearoa Clinical Trials, Auckland, New Zealand.
- CRISPR Therapeutics, Boston.
ORCID-Profile: Ashish Sarraju, Steven E Nissen
Förderung
- CRISPR Therapeutics
Zitieren
APA
Laffin, L. J., Nicholls, S. J., Scott, R. S., Clifton, P. M., Koops, R., Sarraju, A., Singh, S., Wang, Q., Wolski, K., Xu, H., Nielsen, J., Patel, N., Duran, J. M., & Nissen, S. E. (2026). Durability of CRISPR-Cas9 Gene Editing Targeting ANGPTL3 with CTX310. New England Journal of Medicine, 395(13), 1343-1345. https://doi.org/10.1056/nejmc2609825
Vancouver
Laffin LJ, Nicholls SJ, Scott RS, Clifton PM, Koops R, Sarraju A, et al. Durability of CRISPR-Cas9 Gene Editing Targeting ANGPTL3 with CTX310. New England Journal of Medicine. 2026;395(13):1343-1345. doi:10.1056/nejmc2609825
BibTeX
@article{Laffin2026,
author = {Laffin, Luke J and Nicholls, Stephen J and Scott, Russell S and Clifton, Peter M and Koops, Renate and Sarraju, Ashish and Singh, Shweta and Wang, Qiuqing and Wolski, Kathy and Xu, Huansheng and Nielsen, Jen and Patel, Naimish and Duran, Jason M and Nissen, Steven E},
title = {Durability of CRISPR-Cas9 Gene Editing Targeting ANGPTL3 with CTX310},
journal = {New England Journal of Medicine},
year = {2026},
volume = {395},
number = {13},
pages = {1343--1345},
doi = {10.1056/nejmc2609825}
}
EUVIMED